ANDA 214790, held by Ascent Pharms Inc. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 214790 (Sertraline Hydrochloride), held by Ascent Pharms Inc, was first approved by FDA on May 3, 2021, with 3 approved supplements and 0 published complete response letters.
Sertraline hydrochloride tablets are indicated for the treatment of the following: Major depressive disorder (MDD) Obsessive-compulsive disorder (OCD) Panic disorder (PD) Posttraumatic stress disorder (PTSD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) Sertraline hydrochloride tablets are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of: Major depressive disorder (MDD) Obsessive-compulsive disorder (OCD) Panic disorder (PD) Post-traumatic stress disorder (PTSD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 3, 2021 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 75MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Feb 15, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 10, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 10, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 3, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters